Clinical Trial: A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06938711) titled 'A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer' on May 30, 2023.

Brief Summary: This is a rollover study for patients enrolled in the discontinued ELONA clinical trial (ONA-XR-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in combination.

Study Start Date: June, 2023

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: Elacestrant

Elacestrant 200mg once daily oral dosing in cycles of 28 days.

DRUG: Onapristone

Onapristone 40mg twice daily ...